Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F21%3AE0109141" target="_blank" >RIV/00843989:_____/21:E0109141 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/21:00075847 RIV/00064165:_____/21:10429479
Result on the web
<a href="https://onlinelibrary.wiley.com/doi/10.1002/ajh.26282" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1002/ajh.26282</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/ajh.26282" target="_blank" >10.1002/ajh.26282</a>
Alternative languages
Result language
angličtina
Original language name
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone
Original language description
The assessment of patient-reported outcomes (PROs) has become an important component in clinical trials as they provide information on the impact of a disease and treatment from the patient's perspective. The BOSTON trial is the first study of a bortezomib-based triplet therapy that showed lower rates of overall and Grade ? 2 PN compared with doublet Vd while conferring a longer PFS and fewer clinic visits than standard twice weekly Vd. As the survival of patients with MM are improving, the need to minimize cumulative side effects such as PN becomes more important to improve QoL. The reduction in PN-related pain and sensory symptoms observed with XVd in this setting of increased PFS, time to next therapy, and patient-preferred oral administration supports a potentially improved patient experience and decreased health care burden and long-term morbidity.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
American journal of hematology
ISSN
0361-8609
e-ISSN
1096-8652
Volume of the periodical
96
Issue of the periodical within the volume
10
Country of publishing house
US - UNITED STATES
Number of pages
1
Pages from-to
e383-e386
UT code for WoS article
000671882800001
EID of the result in the Scopus database
2-s2.0-85109791260